Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
A representative image illustrating TNX-103 heart failure clinical research after Tenax Therapeutics’ Phase 3 LEVEL trial missed its primary exercise-capacity endpoint in pulmonary hypertension associated with heart failure with preserved ejection fraction.
Pharma & Biotech

Tenax heart failure drug fails Phase 3 test despite 49% drop in cardiac stress biomarker

TNX-103 misses its Phase 3 LEVEL endpoints as Tenax shares collapse. See why a 26.3-meter subgroup benefit could keep the program alive.

Read More
A representative image illustrating NCX 470 glaucoma treatment research as the nitric oxide-donating eye drop enters regulatory review in China following two positive Phase 3 trials in glaucoma and ocular hypertension.
Pharma & Biotech

NCX 470 moves toward China approval with U.S. review already underway

NCX 470 enters China regulatory review after two positive Phase 3 glaucoma trials. Read why U.S. and China decisions could reshape Nicox.

Read More
Quantum BioPharma’s Lucid-MS has received FDA clearance to proceed into a Phase 2 trial in progressive multiple sclerosis, shifting focus to whether the investigational therapy can translate its neuroprotection and myelin-preservation hypothesis into measurable clinical benefit. Representative image.
Pharma & Biotech

Quantum BioPharma gets FDA clearance to advance Lucid-MS into Phase 2 progressive multiple sclerosis trial

Quantum BioPharma Ltd. (NASDAQ: QNTM) said on August 10, 2026 that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug programme for Lucid-MS, also known as Lucid-21-302, allowing the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 study in progressive multiple sclerosis. The regulatory decision permits clinical development to

Read More
Almirall’s collaboration with CrystalO targets novel ion-channel small molecules for medical dermatology, expanding the company’s drug discovery strategy and early-stage dermatology pipeline. Representative image.
Pharma & Biotech

Why Almirall’s latest China biotech deal could open a new small-molecule route into dermatology

Almirall partners with CrystalO on ion-channel small molecules for dermatology. See why clinical proof of concept is the real test for the deal.

Read More
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More
Akeso advances its breast cancer pipeline as the Phase II AK146D1 study evaluates the TROP2/Nectin-4 bispecific ADC in combination with ivonescimab in advanced HER2-negative breast cancer. Representative image.
Pharma & Biotech

Akeso is betting a dual-target ADC can break through breast cancer’s increasingly crowded treatment field

Akeso starts Phase II testing of AK146D1 plus ivonescimab in advanced breast cancer. See what the dual-target ADC strategy must prove.

Read More
HanchorBio’s collaboration with Taiwan Cancer Moonshot researchers aims to combine multi-omics cancer data with biomarker-driven precision oncology and immunotherapy development, including research relevant to its HCB101 pipeline. Representative image.
Pharma & Biotech

HanchorBio wants biomarkers to sharpen its cancer pipeline. Can Taiwan Cancer Moonshot data deliver?

HanchorBio teams with Taiwan Cancer Moonshot researchers to add multi-omics and biomarker depth to its precision immunotherapy strategy.

Read More
Mabwell’s 9MW0311 and 9MW0321 denosumab biosimilars have passed an ANVISA GMP inspection in Brazil, advancing manufacturing readiness as the company pursues Brazilian marketing authorisation. Representative image.
Pharma & Biotech

Could Brazil become Mabwell’s next denosumab biosimilar market after ANVISA GMP inspection?

Mabwell clears ANVISA GMP inspection for 9MW0311 and 9MW0321, advancing its denosumab biosimilar registration strategy in Brazil.

Read More
Innovent Biologics and Daiichi Sankyo’s VANFLYTA commercialization agreement puts China’s newly diagnosed FLT3-ITD-positive acute myeloid leukemia market in focus as the partners move from regulatory approval toward wider clinical adoption. Representative image.
Pharma & Biotech

What Innovent Biologics’ VANFLYTA deal means for FLT3-ITD AML treatment in China

Innovent Biologics will commercialize Daiichi Sankyo’s VANFLYTA in China after its June approval for newly diagnosed FLT3-ITD AML.

Read More
Silence Therapeutics approaches a key Phase 2 SANRECO trial readout for divesiran in polycythemia vera, with investors and clinicians watching hematocrit control, phlebotomy reduction and the potential of infrequent RNA interference therapy. Representative image.
Pharma & Biotech

What will Silence Therapeutics’ SANRECO Phase 2 results reveal about divesiran in polycythemia vera?

Silence Therapeutics will reveal Phase 2 SANRECO divesiran results in polycythemia vera, testing hematocrit control and phlebotomy reduction.

Read More